^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    carboplatin

    i
    Other names: CBDCA, JM-8, JM8, NSC-241240, NSC-241240, NSC 241240, NSC-241-240
    Company:
    Generic mfg.
    Drug class:
    Tubulin polymerization promoter
    Related drugs:
    12h
    MEMENTO: Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy (clinicaltrials.gov)
    P2, N=14, Not yet recruiting, Amsterdam UMC, location VUmc
    New P2 trial
    |
    CD163 (CD163 Molecule)
    |
    carboplatin • metformin
    12h
    ARIAN: Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (clinicaltrials.gov)
    P2, N=129, Not yet recruiting, Fundación GECP | Trial completion date: Jun 2031 --> Nov 2031
    Trial completion date
    |
    cisplatin • carboplatin • Yutuo (zimberelimab) • Trodelvy (sacituzumab govitecan-hziy)
    12h
    Serplulimab Combined with Chemotherapy in Patients with Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carboplatin • albumin-bound paclitaxel • Hetronifly (serplulimab)
    13h
    Peri-E: Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Shanghai Chest Hospital
    New P2 trial
    |
    carboplatin • Tyvyt (sintilimab) • pemetrexed
    1d
    KEYNOTE-E02: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (clinicaltrials.gov)
    P2, N=692, Recruiting, Seagen Inc. | Trial primary completion date: Apr 2025 --> Feb 2026
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Tivdak (tisotumab vedotin-tftv)
    1d
    A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, BeBetter Med Inc
    New P2 trial
    |
    carboplatin • gemcitabine
    1d
    A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) (clinicaltrials.gov)
    P3, N=726, Not yet recruiting, mAbxience Research S.L.
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • MB12 (pembrolizumab biosimilar)
    1d
    ARC-10: Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (clinicaltrials.gov)
    P2, N=169, Active, not recruiting, Arcus Biosciences, Inc. | Phase classification: P3 --> P2 | Trial primary completion date: Aug 2024 --> May 2027
    Phase classification • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    VENTANA PD-L1 (SP263) Assay
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    1d
    ADAPTHER2-IV: NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (clinicaltrials.gov)
    P2, N=402, Recruiting, West German Study Group | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    carboplatin • docetaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    2d
    Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. (clinicaltrials.gov)
    P1/2, N=380, Not yet recruiting, Shanghai Runshi Pharmaceutical Technology Co., Ltd
    New P1/2 trial
    |
    cisplatin • carboplatin • paclitaxel • everolimus • Stivarga (regorafenib) • etoposide IV • SYHA1813
    2d
    A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (clinicaltrials.gov)
    P1, N=750, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium
    3d
    A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=320, Not yet recruiting, LaNova Medicines Limited
    New P1/2 trial • Combination therapy • Metastases
    |
    carboplatin • docetaxel • Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • Zejula (niraparib)
    4d
    Prospective and exploratory clinical study on the efficacy and safety of Adebrelimab combined with chemotherapy as first-line treatment for unresectable locally advanced, recurrent, or metastatic neuroendocrine carcinoma of the digestive tract (ChiCTR2400088905)
    P=N/A, N=20, Not yet recruiting, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medi
    New trial • Metastases
    |
    cisplatin • carboplatin • etoposide IV • Ariely (adebrelimab)
    4d
    A multicenter, single-arm clinical study of enlonstobart combined with nab-paclitaxel and platinum drugs neoadjuvant therapy for locally advanced cervical cancer (ENLONG-001) (ChiCTR2400090024)
    P4, N=34, Not yet recruiting, Chinese PLA General Hospital; Chinese PLA General Hospital
    New P4 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • Enshuxing (enlonstobart)
    4d
    A multicenter, single-arm clinical study of enlonstobart combined with chemoradiotherapy for locally advanced cervical cancer (ENLONG-003) (ChiCTR2400091264)
    P4, N=50, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of
    New P4 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Enshuxing (enlonstobart)
    4d
    Tislelizumab combined with chemotherapy and all trans retinoic acid for locally advanced or metastatic esophageal squamous cell carcinoma: a prospective, double-blind, multicenter, randomized controlled phase II trial (ChiCTR2400090639)
    P4, N=180, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P4 trial • Metastases
    |
    cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr)
    4d
    Dabilimab in combination with paclitaxel (albumin-bound) and carboplatin neoadjuvant therapy for local advanced head and neck squamous cell carcinoma: a single-center, single-arm, open, Phase II clinica (ChiCTR2400091171)
    P2, N=24, Not yet recruiting, The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital,Sun Yat-sen University
    New P2 trial • Combination therapy • Metastases
    |
    carboplatin • paclitaxel
    4d
    Ivonescimab (AK112) plus paclitaxel and carboplatin in frontline neoadjuvant therapy of advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: a phase II trial (ChiCTR2400090496)
    P2, N=132, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial • Metastases
    |
    carboplatin • paclitaxel • Yidafan (ivonescimab)
    4d
    Neoadjuvant hypofractioned radiotherapy followed by benmelstobart plus chemotherapy for resectable non-small cell lung cancer: A phase II study (ChiCTR2400089423)
    P1, N=150, Recruiting, Jiangsu Cancer Hospital; Jiangsu Cancer Hospital
    New P1 trial
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • benmelstobart (APL-502)
    4d
    A Phase Ⅰ/II Clinical Study of SYS6010 in combination with Enlonstobart ± chemotherapy in patients with locally advanced or metastatic NSCLC and other advanced solid tumor (ChiCTR2400089402)
    P1/2, N=540, Not yet recruiting, Shanghai East Hospital; CSPC Megalith Biopharmaceutical Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • ALK mutation • PD-L1 amplification
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • carboplatin • Enshuxing (enlonstobart)
    6d
    Paxalisib Plus Olaparib or Pembrolizumab/Chemotherapy in Advanced Breast Cancer (ACTRN12624001340527)
    P1, N=24, Not yet recruiting, Kazia Therapeutics
    New P1 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • albumin-bound paclitaxel • paxalisib (GDC-0084)
    6d
    Glo-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2/3, N=210, Recruiting, University of Birmingham | Active, not recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • dexamethasone • Zynlonta (loncastuximab tesirine-lpyl) • Ordspono (odronextamab)
    6d
    Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) (clinicaltrials.gov)
    P2, N=40, Recruiting, Istituto Oncologico Veneto IRCCS | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed
    6d
    NeoTOP: Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status (clinicaltrials.gov)
    P2, N=86, Completed, UNICANCER | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 positive • HER-2 negative • HER-2 negative + HR negative • HER-2 positive + HR negative
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • cyclophosphamide • epirubicin
    7d
    IMpassion132: A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=595, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • carboplatin • gemcitabine • capecitabine
    7d
    TRIFOUR: Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer. (clinicaltrials.gov)
    P1/2, N=116, Recruiting, Cantargia AB | Trial primary completion date: Aug 2026 --> Jun 2025
    Trial primary completion date • Combination therapy • BRCA Companion diagnostic • PARP Companion diagnostic • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation
    |
    PD-L1 IHC 22C3 pharmDx • Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    carboplatin • gemcitabine • nadunolimab (CAN04)
    7d
    Esophagomediastinal fistula during durvalumab plus tremelimumab with chemotherapy in angiotensin-converting enzyme 2-positive non-small cell lung cancer: a case report. (PubMed, Transl Lung Cancer Res)
    The treatment regimen comprised durvalumab, tremelimumab, carboplatin, and nab-paclitaxel. Clinicians should be aware that COVID-19 might be associated with the development of severe irAEs and unexpectedly enhanced antitumor effects. The findings also suggest new fields of study regarding the interaction between viral infection and tumor immune response, which may inform future therapeutic approaches.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation
    |
    carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel • Imjudo (tremelimumab)
    7d
    Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients. (PubMed, Transl Lung Cancer Res)
    The tumor growth inhibitory rate was 99.36% for dabrafenib, trametinib, and osimertinib; 99.25% for osimertinib plus vemurafenib; 98.92% for osimertinib, encorafenib, and cetuximab; and 62.83% for pemetrexed plus carboplatin. NGS analysis identified major resistance mechanisms following the triple-targeted therapy, including the EGFR-dependent pathway, EGFR and BRAF V600E-dependent pathway, and an off-target mechanism. EGFR/BRAF/MEK triple-targeted therapy is an effective and safe approach for treating EGFR-mutated NSCLC patients resistant to EGFR-TKIs with acquired BRAF V600E mutations.
    Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • EGFR mutation • BRAF V600
    |
    Erbitux (cetuximab) • Mekinist (trametinib) • Tagrisso (osimertinib) • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • carboplatin • Braftovi (encorafenib) • pemetrexed
    7d
    STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors (clinicaltrials.gov)
    P1, N=202, Recruiting, Synthekine | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • STK-012
    8d
    Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children (clinicaltrials.gov)
    P=N/A, N=30, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Nov 2024 | Trial primary completion date: Mar 2025 --> Nov 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    carboplatin
    9d
    A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) (clinicaltrials.gov)
    P3, N=851, Active, not recruiting, Merck Sharp & Dohme LLC | N=591 --> 851
    Enrollment change • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • albumin-bound paclitaxel
    9d
    IGF2BP3-dependent N6-methyladenosine modification of USP49 promotes carboplatin resistance in retinoblastoma by enhancing autophagy via regulating the stabilization of SIRT1. (PubMed, Kaohsiung J Med Sci)
    Rescue experiments confirmed the pivotal role of SIRT1 in USP49-mediated CBP resistance. Our findings delineate a novel molecular network involving USP49-mediated autophagy in promoting CBP resistance in RB, offering potential targets for therapeutic intervention to enhance treatment efficacy and improve outcomes for RB patients.
    Journal
    |
    SIRT1 (Sirtuin 1) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
    |
    carboplatin
    9d
    EORTC-1206: Androgen Deprivation Therapy in Advanced Salivary Gland Cancer (clinicaltrials.gov)
    P2, N=149, Completed, European Organisation for Research and Treatment of Cancer - EORTC | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Feb 2024
    Trial completion • Trial completion date • Metastases
    |
    AR expression
    |
    cisplatin • carboplatin • paclitaxel • doxorubicin hydrochloride • bicalutamide • triptorelin
    9d
    A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (clinicaltrials.gov)
    P1, N=830, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • 5-fluorouracil • pemetrexed • oxaliplatin • leucovorin calcium • MK-1084
    10d
    TRANSPARENT: A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer (clinicaltrials.gov)
    P4, N=100, Recruiting, Coherus Biosciences, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    cisplatin • carboplatin • gemcitabine • Loqtorzi (toripalimab-tpzi)
    10d
    Nafamostat mesylate sensitizes ovarian cancer cells to carboplatin by promoting the ZNF24-mediated inhibition of WNT2B. (PubMed, J Toxicol Sci)
    Taken together, NM enhanced the CBP sensitivity of ovarian cancer cells by promoting the ZNF24-mediated inactivation of the WNT2B/Wnt/β-catenin axis. These findings suggest a viable treatment approach for improving CBP resistance in ovarian cancer.
    Journal
    |
    WNT2 (Wnt Family Member 2)
    |
    carboplatin • nafamostat
    10d
    Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma (clinicaltrials.gov)
    P2, N=65, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • Neupogen (filgrastim) • dexrazoxane
    10d
    A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P3 trial • Metastases
    |
    cisplatin • carboplatin • SHR-A2009
    11d
    PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=37, Terminated, Opna Bio LLC | Phase classification: P2a --> P1/2
    Phase classification • Combination therapy • Metastases
    |
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    |
    carboplatin • OPN-2853
    11d
    A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, TYK Medicines, Inc
    New P2 trial • Metastases
    |
    cisplatin • carboplatin • pemetrexed • asandeutertinib (TY-9591)
    11d
    neoMono: Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy with Atezolizumab - CTX Therapy (clinicaltrials.gov)
    P2, N=416, Completed, Palleos Healthcare GmbH | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression • HER-2 negative • ER negative • PGR negative
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • paclitaxel • cyclophosphamide • epirubicin
    11d
    HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy (clinicaltrials.gov)
    P3, N=586, Active, not recruiting, Daiichi Sankyo | Trial primary completion date: Aug 2024 --> May 2024
    Trial primary completion date • Metastases
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • carboplatin • patritumab deruxtecan (U3-1402)